Surpass-4: Tirzepatide As An Alternative To Insulin Glargine In Type 2 Diabetes | Stefano Del Prato

SURPASS-4: Tirzepatide as an alternative to insulin glargine in type 2 diabetes | Stefano Del Prato

Medicine Matters diabetes

Tirzepatide beats insulin glargine in lowering body weight, cardiovascular risk in diabetics

Medical Dialogues

Frias_Tirzepatide: Overview of SURPASS Trials in Patients With Type 2 Diabetes

Cardiometabolic Health Congress (CMHC)

The SURPASS Trials on Tirzepatide: Comparison and Combination With Insulin

ADA 2021 – SURPASS-2: Tirzepatide versus semaglutide in type 2 diabetes | Juan Pablo Frías

Medicine Matters diabetes

ADA 2021 – SURPASS-3: Tirzepatide versus insulin degludec in type 2 diabetes | Francesco Giorgino

Medicine Matters diabetes

The SURPASS Trials on Tirzepatide: Analysis and Clinical Outlook

Diabetic patients might benefit from an insulin-alternative protein | UK News | NewsRme

ADA 2021– SURPASS-5: Tirzepatide in people with insulin-dependent type 2 diabetes | Michelle Welch

Medicine Matters diabetes

Clinical Outcomes and Implications for Tirzepatide from the SURPASS Trials

Tirzepatide versus Semaglutide in Type 2 Diabetes (SURPASS-2) | NEJM | Med Journal Club

Med Journal Club

Tirzepatide: A New Treatment for Diabetes

Medication Quality and Safety Rx

ADA 2021 – The SURPASS trials so far: Tirzepatide, semaglutide, and type 2 diabetes | John Wilding

Medicine Matters diabetes

Peters on Tirzepatide: 'Impressive, but We Need to Know More'

New drug for Type 2 diabetes could help patients with weight loss

Summary of first day at American Diabetes Association annual meeting 2024

Tom Rifai MD FACP DipABLM

Tirzepatide for Weight Loss? Health Coach Reacts to Diabetes Drug Trial

fitforfreelance

Tirzepatide: A New Frontier for Diabetes Management

CorConsult Rx: Evidence-Based Medicine

FDA approve Tirzepatide inj for type 2 diabetes

Soups and shakes diet ‘can put type 2 diabetes into remission’